Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dexmedetomidine for sedation in the ICU or PICU: a review of cost-effectiveness and guidelines
2014	Andalusian Health Technology Assessment Area (AETSA)	[Summary of evidence for efficacy and safety of sofosbuvir in patients with chronic hepatitis c coinfected with human immunodeficiency virus]
2014	NIHR Health Technology Assessment programme	Enzalutamide for the treatment of metastatic hormone relapsed prostate cancer previously treated with a docetaxel-containing regimen
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014	Health Quality Ontario (HQO)	Hemoglobin A1c testing in diabetes: a rapid review
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Tasquinimod for chemotherapy naïve, metastatic hormone-relapsed prostate cancer
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Autologous blood reinfusion system for orthopedic surgery: clinical and cost-effectiveness
2014	Andalusian Health Technology Assessment Area (AETSA)	[Selection criteria for direct antiviral agents for patients with chronic hepatitis c in a severe clinical situation in the SSPA]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014	Institute of Health Economics (IHE)	Effectiveness of screening for endemic antibiotic resistant organisms (AROs) in hospital settings
2014	NIHR Horizon Scanning Centre (NIHR HSC)	TH-302 in combination with doxorubicin for locally advanced or metastatic, unresectable soft tissue sarcoma – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Extracorporeal membrane oxygenation for acute respiratory failure: a review of the clinical effectiveness and guidelines
2014	Andalusian Health Technology Assessment Area (AETSA)	[Updating of selection criteria for direct antiviral agents for patients with chronic hepatitis c in a severe clinical situation in the SSPA]
2014	NIHR Health Technology Assessment programme	The effectiveness of collaborative care for people with memory problems in primary care: results of the CAREDEM case management modelling and feasibility study
2014	NIHR Horizon Scanning Centre (NIHR HSC)	SpaceOAR® perirectal spacing system for prostate cancer radiation
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Vitamin D toxicity associated with different vitamin D dosing regimens: safety
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Stem cell transplantation for biologic-resistant Crohn's disease
2014	NIHR Health Technology Assessment programme	The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014	NIHR Health Technology Assessment programme	Can rapid integrated polymerase chain reaction-based diagnostics for gastrointestinal pathogens improve routine hospital infection control practice? A diagnostic study
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Macy catheter for rectal drug administration
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Extracorporeal membrane oxygenation for cardiac failure: a review of the clinical effectiveness and guidelines
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Remote presence robots in telemedicine
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014	NIHR Health Technology Assessment programme	The SNAP trial: a randomised placebo-controlled trial of nicotine replacement therapy in pregnancy - clinical effectiveness and safety until 2 years after delivery, with economic evaluation
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Acupuncture - areas of application, current evidence and proven indications]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Post-operative cerebrospinal fluid removal: guidelines
2014	Andalusian Health Technology Assessment Area (AETSA)	[Communication strategies with children and adolescents in the hospital or primary care setting]
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Ablative techniques for the treatment of localised prostate cancer
2014	NIHR Health Technology Assessment programme	The SNAP trial: a randomised placebo-controlled trial of nicotine replacement therapy in pregnancy; effectiveness and safety until 2 years after delivery, with economic evaluation
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting with uncomplicated symptomatic gallstones or cholecystitis: a systematic review and economic evaluation
2014	NIHR Horizon Scanning Centre (NIHR HSC)	CoVa™ Monitoring System for congestive heart failure
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Opportunities and strategies to drive appropriate use of MRI in Austria
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Islet cell transplantation in patients with unstable diabetes: a review of clinical- and cost-effectiveness and guidelines
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Theralite for treatment of renal failure in patients with multiple myeloma
2014	NIHR Health Technology Assessment programme	Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year olds
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014	NIHR Health Technology Assessment programme	Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Kangaroo™ feeding tube with IRIS technology for aid in nasogastric tube placement
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Idelalisib (Zydelig(R)) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Azelastine - HCl and fluticasone propionate
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Drug-eluting stents with CD34 antibodies for the treatment of coronary artery disease
2014	NIHR Health Technology Assessment programme	Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures: a systematic review and cost-effectiveness analysis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine testing in long-term care: guidelines
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Online programs for weight loss
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Lyophilized plasma for the treatment of adults with hemorrhagic shock: clinical and cost-effectiveness, safety, and guidelines
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Aflibercept solution (Eylea) for visual impairment due to macular oedema secondary to branch retinal vein occlusion
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Vasoprotectives: efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoids
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Retinal surgeries in non-hospital facilities: clinical and cost-effectiveness
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Sutureless aortic valve replacement in patients with severe aortic valve stenosis
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Pertuzumab (Perjeta) for HER2-positive locally advanced, inflammatory or early breast cancer – neo-adjuvant in combination with trastuzumab and docetaxel
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Suboxone versus methadone for the detoxification of patients addicted to prescription opioids: a review of comparative clinical effectiveness, safety, and guidelines
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism spectrum disorder (ASD)]
2014	University of York	Dementia carers. Effective information, support and services to meet their needs
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Balloon sinuplasty for chronic rhinosinusitus
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Pacritinib for myelofibrosis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up]
2014	University of York	Preventing falls in hospitals
2014	NIHR Horizon Scanning Centre (NIHR HSC)	SoftVue™ system for diagnostic breast imaging
2014	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[High-dose rate brachytherapy in the treatment of mobile tongue cancer]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Immediate initiation of continuous positive airway pressure compared with delayed initiation: clinical effectiveness and guidelines
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Implantable carotid sinus baroreflex device for treatment of drug resistant hypertension
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Paclitaxel poliglumex (Xyotax) for advanced ovarian cancer – maintenance therapy
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	iTClamp for controlling compressible gemorrhage in adults: clinical effectiveness, cost-effectiveness, and safety
2014	University of York	Impact of early warning systems on patient outcomes
2014	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Sialendoscopy for the management of obstructive salivary gland disease]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Triple therapy for hepatitis C in previous non-responders: a review of the clinical effectiveness and safety
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Basic fibroblast growth factor (b-FGF) for the treatment of tympanic membrane perforation
2014	Medical Advisory Secretariat (MAS)	Multiple intravenous infusions. Part II
2014	NIHR Health Technology Assessment programme	The effectiveness of sexual health interventions for people with severe mental illness: a systematic review
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Necitumumab in combination with gemcitabine and cisplatin for advanced and metastatic non-small cell lung cancer – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Nutritional supplementation for patients with cancer: a review of the clinical effectiveness and guidelines
2014	University of York	Preventing falls in the community
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Sofosbuvir for the treatment of patients with genotype 4 hepatitis C: a review of the clinical efficacy, cost-effectiveness, and guidelines
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	New and emerging orthopaedic technologies in the Australian and New Zealand public health services
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Midostaurin for newly diagnosed FLT3-mutated acute myeloid leukaemia – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Interventions for non-elderly patients who are high users of ambulatory and emergency medical services: clinical and cost-effectiveness
2014	University of York	Preventing pressure ulcers
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Miethke proSA adjustable gravitational shunt for hydrocephalus
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Custirsen for locally advanced or metastatic hormone-relapsed prostate cancer – first and second line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Non-invasive prenatal testing: a review of the cost effectiveness and guidelines
2014	Institute for Clinical Evaluative Sciences (ICES)	Health outcomes for better information and care (HOBIC): acute care and home care in Ontario 2013
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Profile of individuals insured by the public prescription drug insurance plan who have received treatment for hepatitis C (HCV)]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Collagenase Clostridium histolyticum (Xiapex) for Peyronie's disease – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Foley catheter removal following hip surgery in elderly patients: benefits, harms, and guidelines
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	HPV OncoTect E6, E7 mRNA assay to guide colposcopy referral in cervical cancer screening
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Lumacaftor and ivacaftor combination therapy for cystic fibrosis – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Trientine for treatment of Wilson's disease: clinical and cost-effectiveness, and safety
2014	Institute for Clinical Evaluative Sciences (ICES)	Ontario stroke evaluation report 2014: Ontario stroke report cards
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Use of intravenous immunoglobulins - a review of management strategy experiences and the available evidence]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	SYMBIS for neurosurgery and spine application: clinical and cost-effectiveness
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	SentiMag and Sienna+ for sentinel lymph node localisation in breast cancer
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Velcalcetide for secondary hyperparathyroidism – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Magnetic resonance spectroscopic imaging for prostate disease detection: clinical and cost-effectiveness, and guidelines
2014	Institute for Clinical Evaluative Sciences (ICES)	900,000 days in hospital: The annual impact of smoking, alcohol, diet and physical activity on hospital use in Ontario
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Stereotactic Body Radiation Therapy (SBRT)]